Oncology Biologics Library Entry

ISO 17025–ACCREDITED LABORATORY ENVIRONMENT

Biologics and Novel Therapeutics DMPK and Bioanalytical Services

Creative Proteomics provides DMPK, bioanalytical, PK exposure, immunogenicity-related, and biomarker-linked support for oncology biologics and novel therapeutic research. This section helps researchers explore analytical strategies for monoclonal antibodies, antibody-drug conjugates, and related large-molecule or hybrid therapeutic formats.

Unlike small-molecule oncology agents, biologics and ADCs often require workflows that evaluate molecular exposure, target binding, receptor-mediated disposition, immune response, conjugation stability, payload release, and matrix-specific assay performance.

Explore Biologics Classes Explore Related Services

Large-Molecule ExposureIntact antibody, total antibody, conjugated antibody, and serum PK workflows.

Target & Immune ResponseFree / total target, receptor occupancy, ADA / NAb-related support, and soluble biomarkers.

ADC Payload LogicTotal antibody, conjugated antibody, released payload, catabolites, and linker stability.

Biologic Study Logic Format → Binding → Exposure

🧬

Therapeutic FormatMonoclonal antibody, ADC, hybrid biologic, or related oncology large-molecule format

🎯

Target EngagementFree and total target, receptor occupancy, soluble ligand, or pathway biomarker response

🧪

Exposure & Assay PlatformLigand-binding assays, LC-MS/MS, hybrid immunocapture workflows, serum, plasma, tissue, or tumor matrices

💠

ADC-Specific AnalytesTotal antibody, conjugated antibody, free payload, catabolites, DAR-related context, and linker stability

Biologics Library

Explore Biologics and Novel Therapeutic Classes

mAb

Monoclonal Antibodies

mAb studies often connect intact antibody exposure with target engagement, free / total target measurement, receptor-mediated disposition, and immunogenicity-related support.

Intact antibody quantification
PK exposure assessment
Target engagement support
ADA / NAb-related support

Explore →

ADC

Antibody-Drug Conjugates (ADCs)

ADC workflows may require total antibody, conjugated antibody, free payload, catabolite, linker stability, and tissue exposure analysis in the same study design.

Total antibody exposure
Conjugated ADC analysis
Free payload quantification
Linker stability support

Explore →

Research Questions in Biologics Studies

Which Molecular Form Should Be Measured?

Biologics and novel oncology therapeutics usually require assay strategies built around molecular format, target binding, immune response, and exposure interpretation rather than only parent-drug quantification.

What molecular form matters?The relevant analyte may be intact antibody, total antibody, active binding form, conjugated antibody, free payload, or released catabolite.

Is target engagement needed?Free target, total target, receptor occupancy, soluble ligand, or pathway biomarkers may be required with exposure data.

Is immunogenicity relevant?ADA or NAb-related support may be needed when immune response could affect exposure, clearance, or target binding.

Does the ADC need payload analysis?ADC studies often require payload quantification, catabolite analysis, linker stability, and total-versus-conjugated antibody comparison.

Is receptor-mediated disposition important?Target-mediated drug disposition, FcRn recycling, receptor binding, or tissue uptake may influence exposure patterns.

Which assay platform fits?Ligand-binding assays, LC-MS/MS, hybrid immunocapture-LC-MS/MS, or integrated workflows may be needed depending on analyte and matrix.

Exposure • Target Binding • Payload Behavior

Connecting Biologic Exposure with Target Engagement and Payload Behavior

Biologic and ADC bioanalysis is most useful when exposure data are interpreted in relation to molecular form and mechanism. A single concentration value may not show whether the antibody binds its target, whether immune response affects exposure, or whether an ADC remains conjugated.

Molecular exposureMeasure intact antibody, total antibody, conjugated antibody, or serum exposure over time.

→

Target bindingEvaluate free / total target, receptor occupancy, soluble ligand, or target abundance.

Immune response contextAssess ADA / NAb-related effects, matrix interference, and exposure impact when needed.

→

ADC payload behaviorTrack released payload, catabolites, linker stability, and conjugation-related exposure.

Assay platformSelect LBA, LC-MS/MS, hybrid immunocapture-LC-MS/MS, or combined workflows.

→

Study outputFormat-aware bioanalytical data for biologics and ADC research workflows.

Biologics Research Focus and Potential Readouts

Research Focus	Potential Analytical or Response Readouts
Monoclonal antibody PK	Intact antibody concentration, serum exposure, clearance profile
Target engagement	Free target, total target, receptor occupancy, soluble ligand measurement
Immunogenicity-related assessment	ADA-related support, NAb-related support, exposure impact interpretation
ADC exposure	Total antibody, conjugated antibody, antibody-conjugated payload
Payload release	Free payload, catabolites, linker stability, payload-related metabolites
Tissue or tumor exposure	Tumor homogenate, tissue distribution, target-dependent uptake
Biomarker-linked interpretation	Cytokines, pathway markers, target abundance, response-associated readouts

Bioanalytical and DMPK Service Options

Service Modules for Biologics and ADC Studies

Creative Proteomics supports biologics and novel therapeutic research through platform-aware workflows that connect molecular exposure, target engagement, immune response, ADC payload behavior, and biomarker interpretation.

mAb PK and Target Engagement

Support exposure and target-related analysis for monoclonal antibody research using ligand-binding, LC-MS/MS, or hybrid workflows.

Intact antibody quantification
Serum or plasma PK analysis
Free and total target measurement
Receptor occupancy support
Target engagement biomarkers

Immunogenicity-Related Support

Support ADA / NAb-related assay planning and interpretation when immune response may affect exposure, binding, or PK behavior.

ADA-related assay support
NAb-related support
Matrix interference evaluation
Exposure impact interpretation
Fit-for-purpose assay development

ADC

ADC Exposure and Payload Analysis

Support integrated ADC bioanalysis across antibody exposure, conjugation status, payload release, catabolites, and stability endpoints.

Total antibody quantification
Conjugated ADC exposure
Free payload quantification
Payload catabolite analysis
Linker stability support

Tissue Exposure and Biomarkers

Support matrix-specific bioanalysis and biomarker workflows for studies requiring tumor exposure, target uptake, or immune markers.

Tumor and tissue exposure
Target-dependent uptake
Cytokine and immune markers
Target abundance measurement
Exposure-response interpretation

Related Services

Relevant Services for Biologics and Novel Therapeutic Projects

These service modules can be combined based on therapeutic format, target biology, assay platform, matrix type, payload structure, expected exposure range, and study objective.

Ready to Quantify Your Lead Compound or Metabolite?

Share your matrix type, sample count, and expected range—feasibility routing will confirm whether direct quantification is fit-for-purpose or method development is recommended.

Want to browse compounds, matrices, and assay coverage? Explore the Library →